A look at some of the latest stock recommendations by analysts. These stocks are expected to return between 13% and 43% as per analyst price targets.
DIVI’S LABORATORIES
BROKERAGE: CITI Price Target: Rs 7,050 CMP: Rs 6,216 | Upside: 13%
- Orforglipron, Eli Lilly’s oral diabetes drug, next addition in Divi’s pipeline
- Potential to become primary supplier Company has announced $170-million capex, which Citi believes is primarily for GLP-1—medication to manage
- Type 2 diabetes and obesity Divi’s could be a key player for Eli Lilly’s next weight loss product—Retatrutide
DEVYANI INTERNATIONAL
BROKERAGE: BERNSTEIN Price Target: Rs 220 CMP: Rs 179 | Upside: 23%
- Reiterate positive view after acquiring majority stake in unlisted Sky Gate Hospitality, which owns Biryani By Kilo and other cloud kitchens
- Value accretive for Devyani as deal done at 2-2.5 times sales
- QSR (Quick Service Restaurant) chains at 4-6.6 times sales FY25 and FY26 earnings to be volatile because of M&A and growth moves
ANANT RAJ
BROKERAGE: NOMURA Price Target: Rs 700 CMP: Rs 488 | Upside: 43%
- Reiterate Buy rating but cut price target from Rs 750 to Rs 700 citing a more conservative stance on its data centre unit
- Company’s 307 Mega Watt Data Centre target will be reached by FY32-33 as against earlier expectations of FY31
- Valuations still attractive as earnings per share estimated to grow over 40% on a compounded basis over FY26-27
